Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-22T16:23:47.041Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of Biperiden and Amantadine on Memory in Medicated Chronic Schizophrenic Patients

A Double-blind Cross-over Study

Published online by Cambridge University Press:  02 January 2018

H. Silver  and
N. Geraisy
H. Silver*
Affiliation:
Flugelman (Mazra) Psychiatric Hospital, Israel
N. Geraisy
Affiliation:
Flugelman (Mazra) Psychiatric Hospital, Israel
*
Dr H. Silver, Flugelman (Mazra) Psychiatric Hospital, Doar Na Ashrat, Israel
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The effects on memory of an anticholinergic (biperiden) and a dopaminergic (amantadine) anti-Parkinsonian agent were compared.

Method

Twenty-six chronically medicated schizophrenic (DSM–III–R) in-patients received amantadine (200 mg/day) or biperiden (4 mg/day) for two weeks in a double-blind cross-over design.

Results

Biperiden treatment was associated with significantly lower scores on Benton Visual Retention Test (P < 0.003) and the visual subscale of Wechsler Memory Scale (WMS) (P ≤ 0.02), with a trend to poorer scores on WMS total (P = 0.086) and the digit span (P = 0.07) and logical memory (P = 0.06) subscales.

Conclusions

In usual clinical doses, biperiden interferes with memory, particularly visual, more than amantadine.

Type
Papers
Information
The British Journal of Psychiatry , Volume 166 , Issue 2 , February 1995 , pp. 241 - 243
Copyright
Copyright © 1995 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
Caley, A. (1983) Anticholinergic drugs and memory. British Journal of Psychiatry, 143, 422–423.Google Scholar
Fayen, M., Goldman, M. B., Moulthrop, M. A., et al (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. American Journal of Psychiatry, 145, 483–486.Google Scholar
Gelenberg, A. J., Van Putten, T., Lavori, P. W. W., et al (1989) Anticholinergic effects on memory: benztropine versus amantadine. Journal of Clinical Psychopharmacology, 9, 180–185.CrossRefGoogle ScholarPubMed
Green, M. & Walker, E. (1986) Attentional performance in positive and negative symptom schizophrenia. Journal of Nervous and Mental Disease, 174, 208–213.Google Scholar
King, D. J. (1990) The effect of neuroleptics on cognitive and psychomotor function. British Journal of Psychiatry, 157, 799–811.CrossRefGoogle ScholarPubMed
Lezak, M. D. (1983) Neuropsychological Assessment (2nd edn). Oxford: Oxford University Press.Google Scholar
McEvoy, J. P. (1987) A double-blind crossover comparison of antiparkinsonian drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Journal of Clinical Psychiatry, 48 (suppl. 9), 20–23.Google ScholarPubMed
Patamianos, G. & Kellett, J. M. (1982) Anticholinergic drugs and memory. The effects of benzhexol on memory in a group of geriatric patients. British Journal of Psychiatry, 140, 470–472.Google Scholar
Saykin, A. J., Gur, R. C., Gur, R. E., et al (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Archives of General Psychiatry, 48, 618–624.Google Scholar
Tamlyn, D., McKenna, R. J., Mortimer, A. M., et al (1992) Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychological Medicine, 22, 101–115.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.